- Conditions
- ADHD, Autism, Bipolar I Disorder, Conduct Disorder, Oppositional Defiant Disorder
- Interventions
- Brexpiprazole
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • Rogers, Arkansas • Long Beach, California + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 7,383
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic, Melanoma, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Pancreatic Cancer
- Interventions
- Radiotherapy, MEDI4736, Tremelimumab
- Radiation · Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cholangiocarcinoma
- Interventions
- Pemigatinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 49
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Tempe, Arizona + 46 more
- Conditions
- Parenting, Eating Behavior, Diet, Healthy, Pediatric Obesity
- Interventions
- Measurement
- Other
- Lead sponsor
- Temple University
- Other
- Eligibility
- 4 Years to 5 Years
- Enrollment
- 416 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Houston, Texas
- Conditions
- Advanced Cancer
- Interventions
- BMS-986258, Nivolumab, rHuPH20
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Aurora, Colorado • Iowa City, Iowa + 6 more
- Conditions
- Peritoneal Carcinomatosis
- Interventions
- Mitomycin C (MMC), Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC)
- Drug · Device
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Advanced Melanoma, Metastatic Melanoma
- Interventions
- Nivolumab, Ipilimumab
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Chicago, Illinois • Lutherville, Maryland + 7 more
- Conditions
- CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type, Anaplastic Large Cell Lymphoma, ALK-Positive, Peripheral T-cell Lymphoma, Anaplastic Large Cell Lymphoma, ALK-negative, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
- Interventions
- C7R.CD30.CAR-EBVST cells
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2043
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Myelodysplastic Syndrome Acute Myeloid Leukemia
- Interventions
- Nivolumab
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Mental Health Issue, COVID-19
- Interventions
- in person meditation, in person meditation using headphones, virtual meditation
- Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut
- Conditions
- Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
- Interventions
- atumelnant (CRN04894)
- Drug
- Lead sponsor
- Crinetics Pharmaceuticals Inc.
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 8
- States / cities
- Pasadena, California • Ann Arbor, Michigan • Minneapolis, Minnesota + 5 more
- Conditions
- Neoplasms, Lymphoma
- Interventions
- MLN9708, Nelfinavir
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Atherosclerosis
- Interventions
- Rosuvastatin 10 mg, Darapladib 160 mg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 20 Years to 64 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Tobacco Use Disorder, Smoking Cessation
- Interventions
- Web-based curriculum on tobacco dependence treatment, Tobacco Counseling Role Play, Preceptor Training and Teaching Medical Students, Booster Session
- Behavioral
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Stanford, California • Washington D.C., District of Columbia + 10 more
- Conditions
- Healthy Volunteers
- Interventions
- Fasinumab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 20 Years to 55 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
- Interventions
- AMXT1501, DFMO
- Drug
- Lead sponsor
- Aminex Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 4
- States / cities
- Austin, Texas • Houston, Texas • San Antonio, Texas + 1 more
- Conditions
- Peripheral Arterial Disease
- Interventions
- Advanta VXT Vascular Graft, Flixene Vascular Graft
- Device
- Lead sponsor
- Atrium Medical Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Onartuzumab, Sorafenib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 5
- States / cities
- Sarasota, Florida • Baltimore, Maryland • New York, New York + 2 more
- Conditions
- Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
- Interventions
- Ipilimumab, Nivolumab, Pembrolizumab, Quadrivalent Inactivated Influenza Vaccine, Resection, Nivolumab + Relatlimab
- Biological · Procedure
- Lead sponsor
- Carlo Contreras
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- JNJ 28431754, Placebo
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI)
- Interventions
- Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab + Relatlimab, Prednisone, Docetaxel, DDI Probe Cocktail
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,394 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 38 more
- Conditions
- Prostatic Neoplasms
- Interventions
- Radiotherapy, LHRHa, Apalutamide
- Radiation · Drug
- Lead sponsor
- Janssen Pharmaceutica N.V., Belgium
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 691 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2031
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 10 more
- Conditions
- Recurrent Respiratory Papillomatosis, Papillomavirus Infection, Papillomaviridae
- Interventions
- Zopapogene imadenovec (Zopa)
- Drug
- Lead sponsor
- Precigen, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Bethesda, Maryland • Cincinnati, Ohio
- Conditions
- Relapsed and/or Refractory B-cell Lymphoma
- Interventions
- Cyclophosphamide, Fludarabine, KITE-363, KITE-753
- Drug · Biological
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 21
- States / cities
- Gilbert, Arizona • Duarte, California • Stanford, California + 17 more